Nurix Therapeutics, Inc.
NRIX · NASDAQ
11/30/2024 | 11/30/2023 | 11/30/2022 | 11/30/2021 | |
|---|---|---|---|---|
| Revenue | $54,549 | $76,987 | $38,627 | $29,750 |
| % Growth | -29.1% | 99.3% | 29.8% | – |
| Cost of Goods Sold | $221,632 | $189,148 | $184,497 | $116,434 |
| Gross Profit | -$167,083 | -$112,161 | -$145,870 | -$86,684 |
| % Margin | -306.3% | -145.7% | -377.6% | -291.4% |
| R&D Expenses | $221,632 | $189,148 | $184,497 | $116,434 |
| G&A Expenses | $45,944 | $42,902 | $37,997 | $31,202 |
| SG&A Expenses | $45,944 | $42,902 | $37,997 | $31,202 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$221,632 | -$189,148 | -$184,497 | -$116,434 |
| Operating Expenses | $45,944 | $42,902 | $37,997 | $31,202 |
| Operating Income | -$213,027 | -$155,063 | -$183,867 | -$117,886 |
| % Margin | -390.5% | -201.4% | -476% | -396.3% |
| Other Income/Exp. Net | $19,728 | $11,115 | $3,507 | $823 |
| Pre-Tax Income | -$193,299 | -$143,948 | -$180,360 | -$117,063 |
| Tax Expense | $270 | $0 | $0 | $131 |
| Net Income | -$193,569 | -$143,948 | -$180,360 | -$117,194 |
| % Margin | -354.9% | -187% | -466.9% | -393.9% |
| EPS | -2.88 | -2.65 | -3.71 | -2.73 |
| % Growth | -8.7% | 28.6% | -35.9% | – |
| EPS Diluted | -2.88 | -2.65 | -3.71 | -2.73 |
| Weighted Avg Shares Out | 67,120 | 54,338 | 48,608 | 42,895 |
| Weighted Avg Shares Out Dil | 67,120 | 54,338 | 48,608 | 42,895 |
| Supplemental Information | – | – | – | – |
| Interest Income | $19,728 | $11,115 | $3,507 | $823 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $8,018 | $6,133 | $4,149 | $1,990 |
| EBITDA | -$205,009 | -$148,930 | -$179,718 | -$115,896 |
| % Margin | -375.8% | -193.4% | -465.3% | -389.6% |